-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $293

Benzinga·11/20/2026 16:22:18
语音播报
BMO Capital analyst David Lebowitz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target from $292 to $293.